Inhibitor Therapeutics(INTI)
$0.080.00 (0.00%)
INTI
Inhibitor Therapeutics financials statements
$0.08
At close:0.00 (0.00%)
Inhibitor Therapeutics (INTI) Ratios
32 Followers
Inhibitor Therapeutics Ratios
INTI's free cash flow for Q3 2026 was $-369.56K. For the 2026 fiscal year, INTI's free cash flow was increased by $0.00 and operating cash flow was $-369.56K. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 3.19 | 8.02 | 13.45 | 17.64 | 0.09 |
| Quick Ratio | 3.19 | 8.02 | 13.45 | 17.64 | 0.09 |
| Cash Ratio | 3.10 | 7.90 | 13.29 | 17.61 | 0.05 |
| Solvency Ratio | -0.87 | 0.09 | 0.10 | 3.47 | 0.01 |
| Operating Cash Flow Ratio | -4.22 | -4.56 | -4.06 | 17.30 | -0.32 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 28.57 | -0.95 |
| Net Current Asset Value | $ -1.36M | $ 1.99M | $ 5.28M | $ 8.30M | $ -3.62M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.02 | 0.00 | 0.00 | 0.03 | 3.93 |
| Debt-to-Equity Ratio | -0.05 | 0.00 | 0.00 | 0.05 | -0.06 |
| Debt-to-Capital Ratio | -0.05 | 0.00 | 0.00 | 0.05 | -0.07 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | -1.94 | 2.87 | 1.69 | 1.44 | -0.02 |
| Debt Service Coverage Ratio | 0.00 | 0.00 | 0.00 | -0.13 | -1.32 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | -28.32 | -21.90 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 |
| Interest Debt Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Debt to EBITDA | 0.68 | -17.63 | -23.33 | 155948.97 | -0.62 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 99.55% | 100.00% |
| EBT Per EBIT | 96.31% | 91.30% | 88.87% | -1848.18% | 92.00% |
| Return on Assets (ROA) | -131.42% | -58.63% | -33.81% | 101.09% | -508.64% |
| Return on Equity (ROE) | 255.46% | -168.21% | -57.27% | 145.92% | 8.26% |
| Return on Capital Employed (ROCE) | -196.37% | -73.36% | -41.10% | -5.82% | 52.35% |
| Return on Invested Capital (ROIC) | -193.63% | -73.36% | -41.10% | -5.59% | 83.37% |
| Return on Tangible Assets | -131.42% | -58.63% | -33.81% | 101.09% | -508.64% |
| Earnings Yield | -42.51% | -32.25% | -21.74% | 33.39% | -0.53% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.02 | -0.02 | -0.02 | 0.03 | -0.00 |
| Free Cash Flow Per Share | -0.02 | -0.02 | -0.02 | 0.03 | -0.00 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | 0.00 | -1350156.00 | 0.00 | 0.00 |
| Capital Expenditure Coverage Ratio | 0.00 | 0.00 | -1350156.00 | 0.00 | 0.00 |
| Operating Cash Flow Coverage Ratio | -52.45 | 0.00 | 0.00 | 28.57 | -0.95 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -41.63% | -31.23% | -19.40% | 32.39% | -0.39% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -2.36 | -3.10 | -4.60 | 2.99 | -188.75 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | -6.01 | 5.22 | 2.63 | 4.37 | -15.59 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -2.40 | -3.20 | -5.16 | 3.09 | -256.03 |
| Price-to-Operating Cash Flow Ratio | -2.40 | -3.20 | -5.16 | 3.09 | -256.03 |
| Price-to-Earnings Growth (PEG) Ratio | 1.52 | 1.03 | 0.03 | -0.00 | 3.52 |
| Enterprise Value Multiple | -1.59 | 14.92 | 13.41 | -333945.84 | -174.27 |
| Enterprise Value | 5.45M | 4.75M | 5.08M | 24.71M | 56.64M |
| EV to EBITDA | -1.59 | 14.92 | 13.41 | -333945.84 | -174.27 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -1.69 | -1.47 | -1.88 | 2.10 | -256.94 |
| EV to Operating Cash Flow | -1.69 | -1.47 | -1.88 | 2.10 | -256.94 |
| Tangible Book Value Per Share | -0.01 | 0.01 | 0.03 | 0.02 | -0.01 |
| Shareholders’ Equity Per Share | -0.01 | 0.01 | 0.03 | 0.02 | -0.01 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -0.02 | -0.02 | -0.02 | 0.03 | -0.00 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 0.96 | 1.00 | 1.00 | -18.48 | 0.66 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.98 | 0.97 | 0.89 | 0.97 | 0.74 |
Currency in USD

